Alterations of multiple alveolar macrophage states in chronic obstructive pulmonary disease
By
Kevin Bassler,
Wataru Fujii,
Theodore S. Kapellos,
Arik Horne,
Benedikt Reiz,
Erika Dudkin,
Malte Lücken,
Nico Reusch,
Collins Osei-Sarpong,
Stefanie Warnat-Herresthal,
Allon Wagner,
Lorenzo Bonaguro,
Patrick Günther,
Carmen Pizarro,
Tina Schreiber,
Matthias Becker,
Kristian Händler,
Christian T. Wohnhaas,
Florian Baumgartner,
Meike Köhler,
Heidi Theis,
Michael Kraut,
Marc H Wadsworth,
Travis K Hughes,
Humberto J G Ferreira,
Jonas Schulte-Schrepping,
Emily Hinkley,
Ines H Kaltheuner,
Matthias Geyer,
Christoph Thiele,
Alex K Shalek,
Andreas Feißt,
Daniel Thomas,
Henning Dickten,
Marc Beyer,
Patrick Baum,
Nir Yosef,
Anna C. Aschenbrenner,
Thomas Ulas,
Jan Hasenauer,
Fabian J. Theis,
Dirk Skowasch,
Joachim L Schultze
Posted 30 May 2020
bioRxiv DOI: 10.1101/2020.05.28.121541
Despite the epidemics of chronic obstructive pulmonary disease (COPD), the cellular and molecular mechanisms of this disease are far from being understood. Here, we characterize and classify the cellular composition within the alveolar space and peripheral blood of COPD patients and control donors using a clinically applicable single-cell RNA-seq technology corroborated by advanced computational approaches for: machine learning-based cell-type classification, identification of differentially expressed genes, prediction of metabolic changes, and modeling of cellular trajectories within a patient cohort. These high-resolution approaches revealed: massive transcriptional plasticity of macrophages in the alveolar space with increased levels of invading and proliferating cells, loss of MHC expression, reduced cellular motility, altered lipid metabolism, and a metabolic shift reminiscent of mitochondrial dysfunction in COPD patients. Collectively, single-cell omics of multi-tissue samples was used to build the first cellular and molecular framework for COPD pathophysiology as a prerequisite to develop molecular biomarkers and causal therapies against this deadly disease. ### Competing Interest Statement A.K.S. has received compensation for consulting and SAB membership from Honeycomb Biotechnologies, Dot Bio, Cellarity, Cogen Therapeutics, and Dahlia Biosciences. C.T.W. and P.B. are employees of Boehringer Ingelheim. B.R., F.B., M.K., and H.D. are employees of Comma Soft AG. F.J.T. reports receiving consulting fees from Roche Diagnostics GmbH and Cellarity Inc., and ownership interest in Cellarity, Inc. and Dermagnostix.
Download data
- Downloaded 1,624 times
- Download rankings, all-time:
- Site-wide: 10,155
- In systems biology: 188
- Year to date:
- Site-wide: 6,224
- Since beginning of last month:
- Site-wide: 5,860
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!